# Semiglazov Vf

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/semiglazov-vf/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,766 |
| Field | Breast Cancer Treatment Studies |
| h-index | 62 |
| i10-index | 120 |
| Last Known Institution | Max Planck Society |
| OpenAlex ID | https://openalex.org/A5068100907 |
| ORCID iD | https://orcid.org/0000-0003-0077-9619 |
| Works | 586 |

## Researcher papers

- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)
- [Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study](https://scholariq.org/papers/preoperative-treatment-of-postmenopausal-breast-cancer-patients-with-letrozole-a/)
- [Challenges to effective cancer control in China, India, and Russia](https://scholariq.org/papers/challenges-to-effective-cancer-control-in-china-india-and-russia/)
- [Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/phase-ii-study-of-temsirolimus-cci-779-a-novel-inhibitor-of-mtor-in-heavily/)
- [Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer](https://scholariq.org/papers/phase-iii-trial-evaluating-the-addition-of-paclitaxel-to-doxorubicin-followed-by/)
- [Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy](https://scholariq.org/papers/feasibility-and-tolerability-of-sequential-doxorubicin-paclitaxel-followed-by/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Max Planck Society](https://scholariq.org/institutions/max-planck-society/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.